 Breda, the Netherlands Ghent, Belgium argenx Euronext Nasdaq: ARGX, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares including ordinary shares represented by American Depositary Shares ADSs, which includes the full exercise of the underwriters option to purchase 548,777 additional ADSs. Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen Co acted as co-managers for the offering. The securities were offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission SEC. 